Asplin C M, Hollander P, Pecoraro R E, Brodsky J, Palmer J P
Diabetes Care. 1981 May-Jun;4(3):337-42. doi: 10.2337/diacare.4.3.337.
To assess the possible value of the use of high-purity pork insulin (HPPI) in the United States, the serum insulin (I), pancreatic polypeptide (PP), glucagon (G), and somatostatin (SRIF) antibody binding characteristics have been determined in 90 conventional insulin-treated diabetic subjects and related to their degree of metabolic control, as assessed by glycosylated hemoglobin (HbA1) concentration. All diabetic subjects had antibodies to insulin, but there was no relationship between any of the antibody binding characteristics and HbA1 level: 47% possessed PP antibodies; mean +/- SEM HbA1 in these patients was 14.5 +/- 0.3%, identical to those without PP antibodies (14.5 +/- 0.4%); 10% had G binding antibodies with HbA1 levels of 14.6 +/- 0.8%, similar to those without G antibodies. No subject possessed SRIF antibodies. This lack of correlation between antibody characteristics and metabolic control makes it unlikely that, in the majority of patients, treatment with a less immunogenic insulin (HPPI) versus conventional insulin will result in improved diabetic control.
为评估在美国使用高纯度猪胰岛素（HPPI）的潜在价值，我们测定了90例接受常规胰岛素治疗的糖尿病患者血清胰岛素（I）、胰多肽（PP）、胰高血糖素（G）和生长抑素（SRIF）的抗体结合特性，并将其与糖化血红蛋白（HbA1）浓度所评估的代谢控制程度相关联。所有糖尿病患者均有胰岛素抗体，但任何抗体结合特性与HbA1水平之间均无关联：47%的患者有PP抗体；这些患者的平均±标准误HbA1为14.5±0.3%，与无PP抗体的患者相同（14.5±0.4%）；10%的患者有G结合抗体，其HbA1水平为14.6±0.8%，与无G抗体的患者相似。无一例患者有SRIF抗体。抗体特性与代谢控制之间缺乏相关性表明，在大多数患者中，使用免疫原性较低的胰岛素（HPPI）而非常规胰岛素进行治疗不太可能改善糖尿病控制情况。
